In a victory for the makers of OxyContin, the Federal Circuit on Wednesday overturned a decision that found patents protecting the powerful painkiller were invalid because the company deliberately misled the U.S. Patent Office. The decision sends the case back to a federal trial court in New York to determine whether Purdue Pharma's patents are enforceable. On another legal front, Purdue Pharma has been named in hundreds of lawsuits for its marketing of OxyContin, but many have been dismissed.
February 03, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
In a victory for the makers of OxyContin, a federal appeals court on Wednesday overturned a decision that found patents protecting the powerful painkiller were invalid because the company deliberately misled the U.S. Patent Office.
The decision by the U.S. Court of Appeals for the Federal Circuit sends the case back to a federal trial court in New York to determine whether Purdue Pharma’s patents are enforceable.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
